UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer [version 3; peer review: 2 approved]

F1000 research, 2021, Vol.9, p.1219-1219

2021

Volltextzugriff (PDF)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

NPJ breast cancer, 2021-09, Vol.7 (1), p.124-124, Article 124

2021

Volltextzugriff (PDF)

Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer

Journal of Oncology, 2017-01, Vol.2017, p.5035371-15

2017

Volltextzugriff (PDF)

Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ

BMC cancer, 2018-02, Vol.18 (1), p.129-129, Article 129

2018

Volltextzugriff (PDF)

WISP2/CCN5 Suppresses Vasculogenic Mimicry through Inhibition of YAP/TAZ Signaling in Breast Cancer Cells

Cancers, 2022-03, Vol.14 (6), p.1487

2022

Volltextzugriff (PDF)

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis

Breast (Edinburgh), 2021-10, Vol.59, p.183-192

2021

Volltextzugriff (PDF)

Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients

Frontiers in oncology, 2021-07, Vol.11, p.678315-678315

2021

Volltextzugriff (PDF)

INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer

Frontiers in oncology, 2021-06, Vol.11, p.653370-653370

2021

Volltextzugriff (PDF)

Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial

Cancers, 2023-03, Vol.15 (7), p.2030

2023

Volltextzugriff (PDF)

Sensitive and Specific Detection of Ewing Sarcoma Minimal Residual Disease in Ovarian and Testicular Tissues in an In Vitro Model

Cancers, 2019-11, Vol.11 (11), p.1807

2019

Volltextzugriff (PDF)

[18F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer

EJNMMI research, 2020-01, Vol.10 (1), p.2-14, Article 2

2020

Volltextzugriff (PDF)

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

NPJ breast cancer, 2020-05, Vol.6 (1), p.17-17, Article 17

2020

Volltextzugriff (PDF)

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

NPJ breast cancer, 2020-05, Vol.6 (1), p.16, Article 16

2020

Volltextzugriff (PDF)

Nestin as a Prognostic Biomarker in High-grade Epithelial Ovarian Cancer Treated by Neoadjuvant Chemotherapy

Anticancer research, 2022-07, Vol.42 (7), p.3583-3594

2022

Volltextzugriff (PDF)

Circulating proteins as predictive and prognostic biomarkers in breast cancer

Clinical proteomics, 2022-07, Vol.19 (1), p.25-25, Article 25

2022

Volltextzugriff (PDF)

Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non–small cell lung cancer treated with immunotherapy

European journal of cancer (1990), 2021-03, Vol.145, p.221-229

2021

Volltextzugriff (PDF)

Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e15537-e15537

2021

Volltextzugriff (PDF)

Abstract P1-08-24: Platelet-to-lymphocyte ratio is worth using with tumor-infiltrating lymphocytes to predict good response to neoadjuvant chemotherapy in triple negative breast cancer: A study on 120 patients

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-08-24

2022

Volltextzugriff (PDF)

STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway

Oncogene, 2021-12, Vol.40 (49), p.6627-6640

2021

Volltextzugriff (PDF)

Neoadjuvant radiotherapy in triple-negative breast cancer: "the past should not steal the present or hide the future"

Reports of practical oncology and radiotherapy, 2022, Vol.27 (1), p.180-181

2022

Volltextzugriff (PDF)

Neoadjuvant radiotherapy in triple-negative breast cancer: "the past should not steal the present or hide the future"

Reports of practical oncology and radiotherapy, 2022-01, Vol.27 (1), p.180-181

2022

Volltextzugriff (PDF)

Abstract 2038: A non-canonical, cell-autonomous STING function protects breast cancer cells from intrinsic and genotoxic-induced DNA instability

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2038-2038

2021

Volltextzugriff (PDF)

Abstract 5803: Homoharringtonine, a natural protein synthesis inhibitor, inhibits growth of triple negative breast cancer in vitro and in vivo

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5803-5803

2018

Volltextzugriff (PDF)

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

NPJ breast cancer, 2021-12, Vol.7 (1), p.150-17, Article 150

2021

Volltextzugriff (PDF)

Tumor mutational burden in non-small cell lung cancer—the pathologist’s point of view

Translational lung cancer research, 2018-12, Vol.7 (5), p.716-721

2018

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(59)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer [version 3; peer review: 2 approved]

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer

Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ

WISP2/CCN5 Suppresses Vasculogenic Mimicry through Inhibition of YAP/TAZ Signaling in Breast Cancer Cells

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis

Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients

INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer

Pathologic Response to Neoadjuvant Sequential Chemoradiation Therapy in Locally Advanced Breast Cancer: Preliminary, Translational Results from the French Neo-APBI-01 Trial

Sensitive and Specific Detection of Ewing Sarcoma Minimal Residual Disease in Ovarian and Testicular Tissues in an In Vitro Model

[18F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Nestin as a Prognostic Biomarker in High-grade Epithelial Ovarian Cancer Treated by Neoadjuvant Chemotherapy

Circulating proteins as predictive and prognostic biomarkers in breast cancer

Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non–small cell lung cancer treated with immunotherapy

Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC)

Abstract P1-08-24: Platelet-to-lymphocyte ratio is worth using with tumor-infiltrating lymphocytes to predict good response to neoadjuvant chemotherapy in triple negative breast cancer: A study on 120 patients

STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway

Neoadjuvant radiotherapy in triple-negative breast cancer: "the past should not steal the present or hide the future"

Neoadjuvant radiotherapy in triple-negative breast cancer: "the past should not steal the present or hide the future"

Abstract 2038: A non-canonical, cell-autonomous STING function protects breast cancer cells from intrinsic and genotoxic-induced DNA instability

Abstract 5803: Homoharringtonine, a natural protein synthesis inhibitor, inhibits growth of triple negative breast cancer in vitro and in vivo

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Tumor mutational burden in non-small cell lung cancer—the pathologist’s point of view

Aktive Filter

Suchergebnisse filtern